12:00 AM
 | 
Mar 18, 2002
 |  BioCentury  |  Strategy

Looking for signs of erosion

Avonex vs. Rebif

Looking for signs of erosion

A marketing war between Biogen Inc. and Serono S.A. might expand the market for interferon-beta therapy by increasing interest in the drugs to treat relapsing-remitting multiple sclerosis (RRMS). But if the market does not expand, BGEN has the most to lose in the U.S. marketplace, as it currently holds a 56% market share.

Serono (SRA; SWX:SEO, Geneva, Switzerland) has said it expects to have about 25% of the...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >